These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 25791363)

  • 21. Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer.
    Sessa C; Perotti A; Noberasco C; De Braud F; Gallerani E; Cresta S; Zucchetti M; Viganò L; Locatelli A; Jimeno J; Feilchenfeldt JW; D'Incalci M; Capri G; Ielmini N; Gianni L
    Eur J Cancer; 2009 May; 45(7):1153-1161. PubMed ID: 19114300
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
    Demetri GD; Chawla SP; von Mehren M; Ritch P; Baker LH; Blay JY; Hande KR; Keohan ML; Samuels BL; Schuetze S; Lebedinsky C; Elsayed YA; Izquierdo MA; Gómez J; Park YC; Le Cesne A
    J Clin Oncol; 2009 Sep; 27(25):4188-96. PubMed ID: 19652065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients.
    Perez-Ruixo JJ; Zannikos P; Hirankarn S; Stuyckens K; Ludwig EA; Soto-Matos A; Lopez-Lazaro L; Owen JS
    Clin Pharmacokinet; 2007; 46(10):867-84. PubMed ID: 17854236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma.
    Ueda T; Kakunaga S; Ando M; Yonemori K; Sugiura H; Yamada K; Kawai A
    Invest New Drugs; 2014 Aug; 32(4):691-9. PubMed ID: 24696229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.
    Pautier P; Floquet A; Chevreau C; Penel N; Guillemet C; Delcambre C; Cupissol D; Selle F; Isambert N; Piperno-Neumann S; Thyss A; Bertucci F; Bompas E; Alexandre J; Collard O; Lavau-Denes S; Soulié P; Toulmonde M; Le Cesne A; Lacas B; Duffaud F;
    Lancet Oncol; 2015 Apr; 16(4):457-64. PubMed ID: 25795402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer.
    LoRusso PM; Jones SF; Koch KM; Arya N; Fleming RA; Loftiss J; Pandite L; Gadgeel S; Weber BL; Burris HA
    J Clin Oncol; 2008 Jun; 26(18):3051-6. PubMed ID: 18565892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies.
    Schwartz GH; Jones CB; Garrison M; Patnaik A; Takimoto C; McCreery H; Skinner M; Tolcher AW; Rowinsky EK
    Invest New Drugs; 2004 Nov; 22(4):437-48. PubMed ID: 15292714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies.
    Awada A; Zhang S; Gil T; de Valeriola D; Lalami Y; De Porre P; Piccart-Gebhart MJ
    Curr Med Res Opin; 2007 May; 23(5):991-1003. PubMed ID: 17519066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.
    LoRusso PM; Infante JR; Kim KB; Burris HA; Curt G; Emeribe U; Clemett D; Tomkinson HK; Cohen RB
    BMC Cancer; 2017 Mar; 17(1):173. PubMed ID: 28264648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.
    Paz-Ares L; López-Pousa A; Poveda A; Balañá C; Ciruelos E; Bellmunt J; del Muro JG; Provencio M; Casado A; Rivera-Herrero F; Izquierdo MA; Nieto A; Tanović A; Cortes-Funes H; Buesa JM
    Invest New Drugs; 2012 Apr; 30(2):729-40. PubMed ID: 20960029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.
    Twelves C; Hoekman K; Bowman A; Vermorken JB; Anthoney A; Smyth J; van Kesteren C; Beijnen JH; Uiters J; Wanders J; Gomez J; Guzmán C; Jimeno J; Hanauske A
    Eur J Cancer; 2003 Sep; 39(13):1842-51. PubMed ID: 12932661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I study of docetaxel and topotecan in patients with solid tumors.
    Tkaczuk KH; Zamboni WC; Tait NS; Meisenberg BR; Doyle LA; Edelman MJ; Hausner PF; Egorin MJ; Van Echo DA
    Cancer Chemother Pharmacol; 2000; 46(6):442-8. PubMed ID: 11138457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I trial of weekly docetaxel, weekly doxorubicin, daily oral cyclophosphamide, and G-CSF (ConTAC regimen) in advanced malignancies.
    Wesolowski R; Peereboom D; Weiss P; Elson P; Thomas Budd G
    Invest New Drugs; 2010 Aug; 28(4):502-8. PubMed ID: 19434371
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies.
    Posey JA; Wang H; Hamilton J; Delgrosso A; Zhang R; Freda T; Zamboni WC
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):182-8. PubMed ID: 15838660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials.
    Le Cesne A; Yovine A; Blay JY; Delaloge S; Maki RG; Misset JL; Frontelo P; Nieto A; Jiao JJ; Demetri GD
    Invest New Drugs; 2012 Jun; 30(3):1193-202. PubMed ID: 21484250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.
    Hing J; Perez-Ruixo JJ; Stuyckens K; Soto-Matos A; Lopez-Lazaro L; Zannikos P
    Clin Pharmacol Ther; 2008 Jan; 83(1):130-43. PubMed ID: 17597713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
    Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
    Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors.
    Masters GA; Brockstein BE; Mani S; Ratain MJ
    Med Oncol; 2003; 20(1):7-12. PubMed ID: 12665678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors.
    Bahleda R; Sessa C; Del Conte G; Gianni L; Capri G; Varga A; Oprea C; Daglish B; Hospitel M; Soria JC
    Invest New Drugs; 2014 Dec; 32(6):1188-96. PubMed ID: 24898305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer.
    Bhargava P; Marshall JL; Fried K; Williams M; Lefebvre P; Dahut W; Hanfelt J; Gehan E; Figuera M; Hawkins MJ; Rizvi NA
    Cancer Chemother Pharmacol; 2001 Aug; 48(2):95-103. PubMed ID: 11561784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.